4 results
Objectives: For patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) enrolled in this study, the objectives are as follows:Primary: -To assess the efficacy of bardoxolone methyl relative to placebo.Secondary…
Primary objective:To establish the safety and toxicity profile of treatment with Ho-166-PLLA-MS.Secondary objectives:• To evaluate tumor response. • To evaluate patient dosimetry. • To evaluate performance status.• To evaluate Quality of Life (QOL…
To determine the accuracy of the URIKA urinary bladder sensor in measuring the distance between the anterior - and posterior wall of the bladder and to determine the range in bladder diameters at which the child should be alarmed to void.
To provide continuing open-label treatment with bardoxolone methyl as part of this extended access program while collecting ongoing safety and tolerability data of bardoxolone methyl.